Hematologic Neoplasms: Clinical Trials

11 trials for Hematologic Neoplasms, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

11 completed. 11 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 411Completed 11

Follow Hematologic Neoplasms: new trials by email Literature Review of Hematologic Neoplasms trials Research Report on Hematologic Neoplasms

Trials (filtered) newest first · largest first

All 11 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome
Pegloticase, Rasburicase - Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Phase 4CompletedM.D. Anderson Cancer Center102022-04-052026-05-06
Study Evaluating SARS-CoV-2 (COVID-19) Humoral Response After BNT162b2 Vaccine in Immunocompromised Adults Compared to Healthy Adults
Biological samples - Kidney Transplant, Myeloma
Phase 4CompletedCentre Hospitalier Régional d'Orléans1962021-03-262025-12-23
Ketamine-ketorolac Versus Fentanyl- Ketorolac I.M in Children During Bone Marrow Biopsy
ketamine-ketorolac, fentanyl- ketorolac - Hematological Malignancy (Leukemia- Lymphoma)
Phase 4CompletedMansoura University802018-08-262020-09-09
Short Versus Extended Antibiotic Treatment With a Carbapenem for High-risk Febrile Neutropenia in Hematology Patients With FUO
Discontinuation of imipenem-cilastatin or meropenem - Febrile Neutropenia, Hematological Malignancy
Phase 4CompletedAmsterdam UMC, location VUmc2762014-12-012019-09-25
The Effect of Special Diets in Hematological Cancer Patients
Special diet - Hematological Malignancy
Phase 4CompletedJens Rikardt Andersen322013-11-012016-08-29
A New Dosing Regimen for Posaconazole Prophylaxis in Children Based on Body Surface Area
Posaconazole prophylaxis 120 mg/m² tid, Blood sampling - Hematological Malignancy
Phase 4CompletedUniversitaire Ziekenhuizen KU Leuven142012-02-012015-03-03
A Trial Comparing Efficacy and Safety of Voriconazole Administered With Therapeutic Drug Monitoring vs. Standard Dosing
Prospective TDM Arm - Fungal Infection
Phase 4CompletedJohns Hopkins University292012-01-012016-08-18
Efficacy of Itraconazole as Secondary Prophylaxis in Patients Undergoing Allogeneic Stem Cell Transplantation or Chemotherapy With Prior Invasive Fungal Infection
Itraconazole - Invasive Fungal Infection
Phase 4CompletedZhejiang University1502008-07-012011-10-14
Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT)
Busulfan, Fludarabine - Myelodysplastic Syndromes, Myeloproliferative Disorders
Phase 4CompletedH. Lee Moffitt Cancer Center and Research Institute722005-08-012017-03-03
A Safety Evaluation of Drotrecogin Alfa (Activated) in Patients With Blood Cancer, Severe Infection Related to Bone Marrow Transplantation
Drotrecogin Alfa (activated) - Sepsis, Hematologic Neoplasms
Phase 4CompletedEli Lilly and Company72003-03-012007-12-07
Intermittent Use of Aerosolized Ribavirin for Treatment of RSV
Ribavirin - Hematological Malignancies
Phase 4CompletedM.D. Anderson Cancer Center512003-02-012012-08-01

Narrower conditions

Neoplasms (2)  ·  Neoplasms, Plasma Cell (2)  ·  Acquired Immunodeficiency Syndrome (1)  ·  Diabetes Mellitus, Type 2 (1)  ·  Febrile Neutropenia (1)  ·  Fever (1)  ·  Hypergammaglobulinemia (1)  ·  Infections (1)  ·  Invasive Fungal Infections (1)  ·  Leukemia, Lymphoid (1)  ·  Lymphoma (1)  ·  Multiple Sclerosis (1)  ·  Mycoses (1)  ·  Myelodysplastic Syndromes (1)

Broader conditions

Hematologic Diseases (11)  ·  Hemic and Lymphatic Diseases (11)  ·  Neoplasms by Site (11)  ·  Neoplasms (9)  ·  Infections (4)  ·  Immune System Diseases (3)  ·  Immunoproliferative Disorders (3)  ·  Pathological Conditions, Signs and Symptoms (3)  ·  Bacterial Infections and Mycoses (2)  ·  Lymphatic Diseases (2)  ·  Lymphoproliferative Disorders (2)  ·  Neoplasms by Histologic Type (2)  ·  Signs and Symptoms (2)  ·  Agranulocytosis (1)  ·  Autoimmune Diseases (1)

Interventions

Amides (1)  ·  Blood Specimen Collection (1)  ·  Busulfan (1)  ·  Carbamates (1)  ·  Cilastatin, Imipenem Drug Combination (1)  ·  Itraconazole (1)  ·  Meropenem (1)  ·  Oxidoreductases (1)  ·  Pegloticase (1)  ·  Ribavirin (1)  ·  Solutions (1)  ·  Urate Oxidase (1)  ·  Uric Acid (1)  ·  Voriconazole (1)  ·  drotrecogin alfa activated (1)

Sponsors

M.D. Anderson Cancer Center (2)  ·  Amsterdam UMC, location VUmc (1)  ·  Centre Hospitalier Régional d'Orléans (1)  ·  Eli Lilly and Company (1)  ·  H. Lee Moffitt Cancer Center and Research Institute (1)  ·  Jens Rikardt Andersen (1)  ·  Johns Hopkins University (1)  ·  Mansoura University (1)  ·  Universitaire Ziekenhuizen KU Leuven (1)  ·  Zhejiang University (1)

Countries

United States (5)  ·  Belgium (1)  ·  China (1)  ·  Denmark (1)  ·  Egypt (1)  ·  France (1)  ·  Netherlands (1)  ·  Romania (1)

Top investigators

Anca Colita, MD (1)  ·  He Huang, MD (1)  ·  Janelle Perkins, PharmD (1)  ·  Jens Rikardt Andersen, MD,MPA (1)  ·  Kieren Marr, MD (1)  ·  Kim Vanstraelen, PharmD (1)  ·  Mark MH Kramer, Prof., MD (1)  ·  Michiel A van Agtmael, MD, PhD (1)  ·  Roy F. Chemaly, MD (1)  ·  Sonja Zweegman, Prof.,MD (1)  ·  Sreedhar Mandayam, MD (1)

Results publications

PMID 22198540, PMID 22927454, PMID 35691326, PMID 39115709

NIH funding

2014 (1)